-
Product Insights
NewExagen Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Exagen Diagnostics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Exagen Diagnostics Inc (Exagen) is a life sciences company that helps patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions. The company’s products include Avise CTD, Avise SLE Prognostic, Avise Infliximab and Avise Adalimumab, Avise HCQ, Avise MTX. Exagen’s products are used for therapeutic drug monitoring of hydroxychloroquine in whole blood and methotrexate polyglutamates, risk...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CTD-401
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CTD-401 Drug Details CTD-401 is under development for the treatment of T-cell acute lymphoblastic...
-
Sector Analysis
Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Pulmonary Arterial Hypertension Market Overview The Pulmonary Arterial Hypertension (PAH) market size across the 7MM was valued at $4.6 billion in 2019 and is forecast to grow at a CAGR of more than 4% during 2019-2029. Pulmonary Arterial Hypertension Market Outlook To gain more information on the Pulmonary Arterial Hypertension market forecast, download a free report sample The Pulmonary Arterial Hypertension market research report provides an overview of PAH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Market Size (2019)...
-
Product Insights
Net Present Value Model: Stalaris
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Stalaris Drug Details efzofitimod (ATYR-1923) is...
-
Product Insights
Net Present Value Model: Bardoxolone Methyl
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Bardoxolone Methyl Drug Details Bardoxolone methyl...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – efzofitimod
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry efzofitimod Drug Details efzofitimod (ATYR-1923) is under development for the treatment of rare pulmonary...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – bardoxolone methyl
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry bardoxolone methyl Drug Details Bardoxolone methyl (RTA 402) is under development for the treatment...
-
Product Insights
Dermatomyositis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dermatomyositis is a rare inflammatory disease that is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. The Bromodomain-containing protein 4 - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Bromodomain-containing protein 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration...
-
Sector Analysis
Canada – Healthcare, Regulatory and Reimbursement Landscape
GlobalData, the industry analysis specialist, has released its latest report: “Canada - Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Canada. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses...